Alan Anthoney

16.4k citations
96 papers · 12.7k · 4 hit papers · h-index 36

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
  • Surgery top 0.2%
    • Cholangiocarcinoma and Gallbladder Cancer Studies

Papers in

    • Pancreatic and Hepatic Oncology Research 19
    • Cancer Treatment and Pharmacology 9
    • Colorectal Cancer Treatments and Studies 5
    • Gastric Cancer Management and Outcomes 6

Alan Anthoney

95 papers receiving 12.4k citations

Alan Anthoney's Hit Papers

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial 2021 · 561 citations
5610+5+10Years since publication1k2k3k

Peers

Alan Anthoney
Comparison fields: 5 of 110
  • Oncology 4.7k
  • Surgery 5.3k
  • Hepatology 244
  • Cancer Research 374
  • Pulmonary and Respiratory Medicine 713
Replace Ignacio Durán with:
Ignacio Durán Spain
Astrid Lièvre France
Jean H. Hoffman-Censits United States
Soonmo Peter Kang United States
Michael Schenker United States
Ravit Geva Israel
Masayuki Sho Japan
Emiliano Calvo Spain
Ani Sarkis Balmanoukian United States
Richard Wayne Joseph United States
Alan Anthoney relative to Ignacio Durán Spain Ignacio Durán's profile →
Citations per field
00.5×2×3.0×
Ignacio Durán · 1×
Citations per year

Countries citing papers authored by Alan Anthoney

Since Specialization
Citations

This map shows the geographic impact of Alan Anthoney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Anthoney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Anthoney more than expected).

Fields of papers citing papers by Alan Anthoney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Anthoney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Anthoney. The network helps show where Alan Anthoney may publish in the future.

Co-authors

The 25 scholars most cited alongside Alan Anthoney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan Anthoney Line = papers co-authored together Alan Anthoney links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 96 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Hit paper breakdown →
20103500
2
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Hit paper breakdown →
20171525
3
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
Hit paper breakdown →
2019942
4
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Hit paper breakdown →
2021561
5 2006491
6 2012463
7 2014347
8 2018333
9 2014327
10 2013284
11 1996269
12 2015235
13 2009225
14 2020215
15 1997214
16 2019204
17 2017200
18
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
1996183
19 2009182
20 2002126

About Alan Anthoney

Alan Anthoney is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Pharmacology, having authored 96 papers that have together received 12.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (19 papers), Cancer therapeutics and mechanisms (12 papers), Cancer Treatment and Pharmacology (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), Gastric Cancer Management and Outcomes (6 papers), Neuroendocrine Tumor Research Advances (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Virus-based gene therapy research (5 papers). The work is most often cited by research in Oncology (4.7k citations), Surgery (5.3k citations), Hepatology (244 citations), Cancer Research (374 citations) and Pulmonary and Respiratory Medicine (713 citations). Alan Anthoney has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Juan W. Valle, David Cunningham, Harpreet Singh Wasan, John A. Bridgewater, Anthony Maraveyas, Daniel H. Palmer, Srinivasan Madhusudan, Timothy J. Iveson, Stephen P. Pereira and Robert Eldon Brown. Their work appears in journals such as British Journal of Cancer, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact